sodium(1+)What was measured
Measured, with no finding
971 endpoints
Show what was measuredHide what was measured
body composition
no effect
By day 14 there were once again no significant differences in body composition between the two groups
PMID 10634837 · one of two readings recorded this
body water compartments
no effect
There were no significant differences between the groups in body water compartments on day 1
PMID 10634837 · one of two readings recorded this
extracellular fluid volume
decreases, p = 0.01
By day 14 the delayed, but not the early group, also had a significant reduction in extracellular fluid volume (delayed -53 ml/kg, p=0.01; early -37 ml/kg, p=0.2)
PMID 10634837 · one of two readings recorded this
extracellular fluid volume
no effect, p = 0.2
By day 14 the delayed, but not the early group, also had a significant reduction in extracellular fluid volume (delayed -53 ml/kg, p=0.01; early -37 ml/kg, p=0.2)
PMID 10634837 · one of two readings recorded this
total body water
decreases
there was a significant loss of total body water during the first week (delayed -44 ml/kg, p=0. 048; early 6 ml/kg, p=0.970)
PMID 10634837 · one of two readings recorded this
total body water
no effect, p = 0.97
there was a significant loss of total body water during the first week (delayed -44 ml/kg, p=0. 048; early 6 ml/kg, p=0.970)
PMID 10634837 · one of two readings recorded this
total body weight (body composition)
modulates, p = 0.013
These changes resulted in a significant alteration in body composition at the end of the first week (total body weight: delayed 791 ml/kg; early 849 ml/kg, p=0.013)
PMID 10634837 · one of two readings recorded this
peak power over eight 15-s intervals of maximal effort arm ergometry, with total work and percent fatigue
no effect, peak power 370.7, 346.3 and 354.3 W across the three treatments, described as similar
Not recorded as a finding: a node exists but the paper states a different instrument or population
However, peak power (370.7 +/- 26.0, 346.3 +/- 13.6, and 354.3 +/- 18.9 W) and total work accomplished in eight intervals (30.2 +/- 1.5, 29.6 +/- 1.1, and 29.9 +/- 1.1 kJ), and percent fatigue (31.0 +/- 2.7, 29.0 +/- 3.2, and 29.2 +/- 4.0%) were similar.
PMID 10731011 · one of two readings recorded this
peak power
no effect, n = 8
peak power (370.7 +/- 26.0, 346.3 +/- 13.6, and 354.3 +/- 18.9 W)
PMID 10731011 · one of two readings recorded this
percent fatigue
no effect, n = 8
percent fatigue (31.0 +/- 2.7, 29.0 +/- 3.2, and 29.2 +/- 4.0%)
PMID 10731011 · one of two readings recorded this
postexercise base excess
increases, n = 8
Postexercise pH (7.02 +/- 0.01, 7.02 +/- 0.03, and 7.09 +/- 0.03) and base excess (-13.29 +/- 0.96, -14.49 +/- 1.01, and -8.83 +/- 1.38) were significantly lower after both PC and NaCl ingestion compared with NaHCO3 ingestion
PMID 10731011 · one of two readings recorded this
postexercise plasma lactate
unclear, n = 8
Postexercise plasma [lactate] was also greater in both PC and NaHCO3 trials (21.42 +/- 1.52, 20.07 +/- 1.39, and 22.65 +/- 1.77 mmol x L(-1))
PMID 10731011 · one of two readings recorded this
postexercise venous pH
increases, n = 8
Postexercise pH (7.02 +/- 0.01, 7.02 +/- 0.03, and 7.09 +/- 0.03) and base excess (-13.29 +/- 0.96, -14.49 +/- 1.01, and -8.83 +/- 1.38) were significantly lower after both PC and NaCl ingestion compared with NaHCO3 ingestion
PMID 10731011 · one of two readings recorded this
preexercise base excess
increases, p = 0.05, n = 8
Preexercise pH (7.33 +/- 0.01, 7.31 +/- 0.01, and 7.40 +/- 0.01) and base excess (2.41 +/- 0.35, 0.93 +/- 0.39, and 8.45 +/- 0.51) after PC and NaCl ingestion, respectively, were similar, whereas ingestion of NaHCO3 resulted in significantly higher values (P < or = 0.05)
PMID 10731011 · one of two readings recorded this
preexercise venous pH
increases, p = 0.05, n = 8
Preexercise pH (7.33 +/- 0.01, 7.31 +/- 0.01, and 7.40 +/- 0.01) and base excess (2.41 +/- 0.35, 0.93 +/- 0.39, and 8.45 +/- 0.51) after PC and NaCl ingestion, respectively, were similar, whereas ingestion of NaHCO3 resulted in significantly higher values (P < or = 0.05)
PMID 10731011 · one of two readings recorded this
total work accomplished in eight intervals
no effect, n = 8
total work accomplished in eight intervals (30.2 +/- 1.5, 29.6 +/- 1.1, and 29.9 +/- 1.1 kJ)
PMID 10731011 · one of two readings recorded this
pulmonary artery pressure estimated by echocardiographic ratio of time to peak velocity to right ventricular ejection time corrected for heart rate (TPV:RVET(c)), sodium 4 mmol/kg/day started 24 hours after birth versus started at 6% weight loss; abstract only
no effect
Not recorded as a finding: the comparison was against another active treatment
There was no difference between the two groups in TPV:RVET(c) measured sequentially after birth.
PMID 11420318 · one of two readings recorded this
pulmonary artery pressure estimated by echocardiographic ratio of time to peak velocity to right ventricular ejection time corrected for heart rate (TPV:RVETc), days 0, 1, 2, 7 and 14
no effect
Not recorded as a finding: the comparison was against another active treatment
There was no difference between the two groups in TPV:RVET(c) measured sequentially after birth.
PMID 11420318 · one of two readings recorded this
TPV:RVET(c) ratio, early versus delayed supplementation
no effect
There was no difference between the two groups in TPV:RVET(c) measured sequentially after birth
PMID 11420318 · one of two readings recorded this
TPV:RVET(c) ratio versus value at birth
increases
in whom a significant fall did not occur until day 14
PMID 11420318 · one of two readings recorded this
TPV:RVET(c) ratio versus value at birth
increases
On within group testing, when compared with values at birth, the ratio was higher by day 3 in the early supplemented group
PMID 11420318 · one of two readings recorded this
total glycemic response, area under the glucose curve in a 75-g oral glucose tolerance test
decreases, 8.0% lower during sodium supplementation
Not recorded as a finding: the paper never states the instrument the node requires
Total glycemic response in the oral GTT (area under the glucose curve) was 8.0% lower during sodium supplementation, P < .001.
PMID 11465650 · one of two readings recorded this
total glycemic response in oral GTT (area under the glucose curve)
decreases, p = 0.001, n = 21
Total glycemic response in the oral GTT (area under the glucose curve) was 8.0% lower during sodium supplementation, P < .001
PMID 11465650 · one of two readings recorded this
total glycemic response in oral GTT (area under the glucose curve)
decreases, n = 6
the effect of sodium was noteworthy in 1) type 2 diabetic subjects (n = 8), 2) sodium-sensitive subjects (n = 10), and 3) nondiabetic subjects receiving antihypertensive drug treatment (n = 6)
PMID 11465650 · one of two readings recorded this
total glycemic response in oral GTT (area under the glucose curve)
decreases, n = 10
the effect of sodium was noteworthy in 1) type 2 diabetic subjects (n = 8), 2) sodium-sensitive subjects (n = 10), and 3) nondiabetic subjects receiving antihypertensive drug treatment (n = 6)
PMID 11465650 · one of two readings recorded this
total glycemic response in oral GTT (area under the glucose curve)
decreases, n = 8
the effect of sodium was noteworthy in 1) type 2 diabetic subjects (n = 8), 2) sodium-sensitive subjects (n = 10), and 3) nondiabetic subjects receiving antihypertensive drug treatment (n = 6)
PMID 11465650 · one of two readings recorded this
total glycemic response in the 75-g oral glucose tolerance test, area under the glucose curve
decreases, 8.0% lower during sodium supplementation
Not recorded as a finding: the paper never states the instrument the node requires
Total glycemic response in the oral GTT (area under the glucose curve) was 8.0% lower during sodium supplementation, P < .001.
PMID 11465650 · one of two readings recorded this
total insulinemic response to oral GTT
decreases
The total insulinemic response to oral GTT was also lowered by sodium loading among diabetic subjects
PMID 11465650 · one of two readings recorded this
urinary sodium excretion
increases, p = 0.001, n = 21
urinary sodium excretion increased on sodium chloride to 267+/-118 mEq/day versus control (placebo) phase of 135+/-53 mEq/day, P < .001
PMID 11465650 · one of two readings recorded this
change in plasma sodium concentration over a 4 h run, replacement fluid at 680 mg/l sodium (H) or 410 mg/l (L) versus water only (W), 1 litre per hour; abstract only
mean decrease in plasma sodium 2.5 (2.5) mmol/l in H vs 6.2 (2.1) mmol/l in W, n = 13
Not recorded as a finding: the direction is carried only as a signed number
The mean (SD) decrease in [Na(+)](plasma) over the whole trial was significantly (p<0.001) less in trial H (2.5 (2.5) mmol/l) than in trial W (6.2 (2.1) mmol/l).
PMID 12893712 · one of two readings recorded this
correlation between changes in plasma sodium and changes in body weight
increases
There was a significant correlation between changes in [Na(+)](plasma) and changes in body weight
PMID 12893712 · one of two readings recorded this
correlation between plasma sodium after the run and performance
no effect
There was no significant correlation between[Na(+)](plasma) after the run and performance
PMID 12893712 · one of two readings recorded this
decrease in plasma sodium over the whole trial
decreases, p = 0.001
The mean (SD) decrease in [Na(+)](plasma) over the whole trial was significantly (p<0.001) less in trial H (2.5 (2.5) mmol/l) than in trial W (6.2 (2.1) mmol/l)
PMID 12893712 · one of two readings recorded this
performance and haematological variables
no effect
No significant differences were found in performance or haematological variables with the three different fluids
PMID 12893712 · one of two readings recorded this
plasma sodium concentration change over a 4-hour run with fluid of 680 mg/l, 410 mg/l or water only; also packed cell volume, mean corpuscular volume, endurance performance
mean decrease in plasma sodium 2.5 (2.5) mmol/l in trial H versus 6.2 (2.1) mmol/l in trial W, p = 0.001
Not recorded as a finding: the direction is carried only as a signed number
The mean (SD) decrease in [Na(+)](plasma) over the whole trial was significantly (p<0.001) less in trial H (2.5 (2.5) mmol/l) than in trial W (6.2 (2.1) mmol/l).
PMID 12893712 · one of two readings recorded this
growth rate
unclear, p = 0.01
a significant difference in growth rate (P < 0.01) observed between the two groups
PMID 1298620 · one of two readings recorded this
osteoblastic activity and protein synthesis
increases
Both groups had increased levels of osteoblastic activity accompanied by high rate of protein synthesis in the supplemented group compared to the non-supplemented one
PMID 1298620 · one of two readings recorded this
serum calcium
decreases, significantly higher in the non-supplemented group
Not recorded as a finding: no outcome node for serum calcium
Results indicated significantly increased serum levels of calcium (P < 0.01) in the non-supplemented group while inorganic phosphate and total protein levels showed significant increase (P < 0.05) in the supplemented group.
PMID 1298620 · one of two readings recorded this
serum calcium
decreases, p = 0.01
Results indicated significantly increased serum levels of calcium (P < 0.01) in the non-supplemented group
PMID 1298620 · one of two readings recorded this
serum inorganic phosphate, serum calcium, total protein, albumin and alkaline phosphatase in VLBW infants supplemented with 3 mMol/kg/day sodium chloride for six weeks versus unsupplemented; direction of the phosphate comparison cannot be told to be between-group or within-group
increases, significant increase in the supplemented group
Not recorded as a finding: another reason, stated per paper
Results indicated significantly increased serum levels of calcium (P < 0.01) in the non-supplemented group while inorganic phosphate and total protein levels showed significant increase (P < 0.05) in the supplemented group.
PMID 1298620 · one of two readings recorded this
serum inorganic phosphate
increases, p = 0.05
while inorganic phosphate and total protein levels showed significant increase (P < 0.05) in the supplemented group
PMID 1298620 · one of two readings recorded this
serum total protein
increases, significant increase in the supplemented group
Not recorded as a finding: no outcome node for serum total protein
Results indicated significantly increased serum levels of calcium (P < 0.01) in the non-supplemented group while inorganic phosphate and total protein levels showed significant increase (P < 0.05) in the supplemented group.
PMID 1298620 · one of two readings recorded this
serum total protein
increases, p = 0.05
while inorganic phosphate and total protein levels showed significant increase (P < 0.05) in the supplemented group
PMID 1298620 · one of two readings recorded this
serum potassium concentration
no effect
while sodium and potassium concentrations were not significantly affected
PMID 1473517 · one of two readings recorded this
serum sodium concentration
no effect
while sodium and potassium concentrations were not significantly affected
PMID 1473517 · one of two readings recorded this
head circumference gain
increases
Determination of weight gain, length gain and head circumference gain showed that these anthropometric parameters are significantly increased by sodium supplementation
PMID 1473517 · one of two readings recorded this
length gain
increases
Determination of weight gain, length gain and head circumference gain showed that these anthropometric parameters are significantly increased by sodium supplementation
PMID 1473517 · one of two readings recorded this
renal excretion of sodium
increases
There were no cases of either hypernatraemia or hyponatraemia though renal excretion of sodium was very high in the supplemented group
PMID 1473517 · one of two readings recorded this
weight gain, length gain and head circumference gain over six weeks in VLBW infants fed own mothers milk; serum and urinary sodium and potassium
increases, significantly increased by sodium supplementation
Not recorded as a finding: a node exists but the paper states a different instrument or population
Determination of weight gain, length gain and head circumference gain showed that these anthropometric parameters are significantly increased by sodium supplementation while sodium and potassium concentrations were not significantly affected.
PMID 1473517 · one of two readings recorded this
weight gain, length gain and head circumference gain over six weeks; sodium and potassium concentrations (serum and urinary, matrix not separated in the sentence)
increases, anthropometric parameters significantly increased by sodium supplementation
Not recorded as a finding: a node exists but the paper states a different instrument or population
Determination of weight gain, length gain and head circumference gain showed that these anthropometric parameters are significantly increased by sodium supplementation while sodium and potassium concentrations were not significantly affected.
PMID 1473517 · one of two readings recorded this
weight gain
increases
Determination of weight gain, length gain and head circumference gain showed that these anthropometric parameters are significantly increased by sodium supplementation
PMID 1473517 · one of two readings recorded this
15-min performance time trial following cycling at 70% of maximal work rate
increases, approximately 7.8% improvement in time trial performance
Not recorded as a finding: a node exists but the paper states a different instrument or population
There was a significant improvement ( approximately 7.8 %; p < 0.05) in time trial performance following IPOSL.
PMID 15776333 · one of two readings recorded this
core temperature
no effect, p = 0.05
No significant differences were observed for heart rate, core temperature, rate of perceived exertion or total body sweat rate (p > 0.05)
PMID 15776333 · one of two readings recorded this
heart rate
no effect, p = 0.05
No significant differences were observed for heart rate, core temperature, rate of perceived exertion or total body sweat rate (p > 0.05)
PMID 15776333 · one of two readings recorded this
performance time trial following a 15-min performance time trial after 45 min cycling at 70% of maximal work rate
increases, approximately 7.8% improvement
Not recorded as a finding: a node exists but the paper states a different instrument or population
There was a significant improvement ( approximately 7.8 %; p < 0.05) in time trial performance following IPOSL.
PMID 15776333 · one of two readings recorded this
plasma volume during exercise
increases
IPOSL maintained plasma volume during exercise to a greater extent than the Pl at 15 and 30, but not 45 min
PMID 15776333 · one of two readings recorded this
plasma volume during exercise
increases
IPOSL maintained plasma volume during exercise to a greater extent than the Pl at 15 and 30, but not 45 min
PMID 15776333 · one of two readings recorded this
plasma volume during exercise
no effect
IPOSL maintained plasma volume during exercise to a greater extent than the Pl at 15 and 30, but not 45 min
PMID 15776333 · one of two readings recorded this
rate of perceived exertion
no effect, p = 0.05
No significant differences were observed for heart rate, core temperature, rate of perceived exertion or total body sweat rate (p > 0.05)
PMID 15776333 · one of two readings recorded this
resting baseline plasma volume change
increases
IPOSL and Pl ingestion lead to a 3.1 % expansion and a 4.7 % reduction in resting baseline plasma volume, respectively
PMID 15776333 · one of two readings recorded this
resting baseline plasma volume change
decreases
IPOSL and Pl ingestion lead to a 3.1 % expansion and a 4.7 % reduction in resting baseline plasma volume, respectively
PMID 15776333 · one of two readings recorded this
time trial performance
increases, p = 0.05
There was a significant improvement ( approximately 7.8 %; p < 0.05) in time trial performance following IPOSL
PMID 15776333 · one of two readings recorded this
total body sweat rate
no effect, p = 0.05
No significant differences were observed for heart rate, core temperature, rate of perceived exertion or total body sweat rate (p > 0.05)
PMID 15776333 · one of two readings recorded this
24 hour urine sodium
n = 17
The mean (SD) urine sodium was 147 (45), 84 (32), and 201 (73) mmol/24 hours in the normal, low, and high sodium intake periods respectively
PMID 1609379 · one of two readings recorded this
24 hour urine sodium
n = 17
The mean (SD) urine sodium was 147 (45), 84 (32), and 201 (73) mmol/24 hours in the normal, low, and high sodium intake periods respectively
PMID 1609379 · one of two readings recorded this
24 hour urine sodium
n = 17
The mean (SD) urine sodium was 147 (45), 84 (32), and 201 (73) mmol/24 hours in the normal, low, and high sodium intake periods respectively
PMID 1609379 · one of two readings recorded this
peak expiratory flow (PEF) and PEF amplitude (highest minus lowest PEF), patient home measurements, across normal, low and high dietary sodium for two weeks
no effect, no significant differences in PEF or PEF amplitude between the three dietary salt periods
Not recorded as a finding: this platform holds no node for the endpoint
There were no significant differences in PEF or PEF amplitude (highest--lowest PEF), an index of asthma lability, between the three dietary salt periods.
PMID 1609379 · one of two readings recorded this
peak expiratory flow (PEF) and PEF amplitude, home measurement by patients, over normal, low and high dietary sodium periods
no effect, no significant differences between the three dietary salt periods
Not recorded as a finding: this platform holds no node for the endpoint
There were no significant differences in PEF or PEF amplitude (highest--lowest PEF), an index of asthma lability, between the three dietary salt periods.
PMID 1609379 · one of two readings recorded this
peak expiratory flow (PEF) and PEF amplitude
no effect, n = 17
There were no significant differences in PEF or PEF amplitude (highest--lowest PEF), an index of asthma lability, between the three dietary salt periods
PMID 1609379 · one of two readings recorded this
additional sodium ingested during the race
Subjects in the sodium supplementation group ingested an additional 3.6 (2.0) g (156 (88) mmol) sodium during the race
PMID 16505084 · one of two readings recorded this
tablets consumed
no effect, p = 0.55
The sodium supplementation group consumed 14.7 (8.3) tablets, and the placebo group took 15.8 (10.1) tablets (p = 0.55; NS)
PMID 16505084 · one of two readings recorded this
area under the curve for systolic blood pressure over 30 and 60 minutes after ingestion of salt water versus water, noninvasive BP, seated
decreases, SBP AUC at 30 minutes 364 with NaCl-H2O versus 714 mm Hg x min with H2O
Not recorded as a finding: a node exists but the paper states a different instrument or population
The area under the curve for SBP was greater with H2O than NaCl-H2O for the 30 minutes (714+/-388 mm Hg x min versus 364+/-369 mm Hg x min; P = 0.002) and 60 minutes (1454+/-827 mm Hg x min versus 812+/-734 mm Hg x min; P = 0.048) after ingestion.
PMID 16785332 · one of two readings recorded this
area under the curve for systolic blood pressure
decreases, p = 0.002
The area under the curve for SBP was greater with H2O than NaCl-H2O for the 30 minutes (714+/-388 mm Hg x min versus 364+/-369 mm Hg x min; P = 0.002)
PMID 16785332 · one of two readings recorded this
area under the curve for systolic blood pressure
decreases, p = 0.048
and 60 minutes (1454+/-827 mm Hg x min versus 812+/-734 mm Hg x min; P = 0.048)
PMID 16785332 · one of two readings recorded this
increase in systolic blood pressure
decreases, p = 0.006
The increase in SBP with H2O was greater than with NaCl-H2O at 30 minutes (37+/-6 versus 18+/-5 mm Hg; P = 0.006)
PMID 16785332 · one of two readings recorded this
increase in systolic blood pressure
no effect, p = 0.4
but not at 60 minutes (17+/-6 versus 10+/-6 mm Hg; P = 0.4)
PMID 16785332 · one of two readings recorded this
norepinephrine
no effect, p = 0.195
Norepinephrine increased after H2O (P = 0.018) but not after NaCl-H2O (P = 0.195)
PMID 16785332 · one of two readings recorded this
norepinephrine
increases, p = 0.018
Norepinephrine increased after H2O (P = 0.018) but not after NaCl-H2O (P = 0.195)
PMID 16785332 · one of two readings recorded this
body mass loss before rehydration
decreases
eight males lost 1.98 +/- 0.1% body mass exercising in the heat
PMID 18463891 · one of two readings recorded this
time to exhaustion at 95% VO2peak after a 5 min bout at 70% VO2peak, 4 h after rehydration with drinks of 1, 31, 40 or 50 mmol/l sodium chloride
no effect, time to exhaustion not different between treatments, p = 0.883
Not recorded as a finding: the comparison was against another active treatment
Time to exhaustion in the exercise capacity test was not different between treatments (P = 0.883).
PMID 18463891 · one of two readings recorded this
time to exhaustion at 95% VO2peak
no effect, p = 0.883, n = 8
Time to exhaustion in the exercise capacity test was not different between treatments (P = 0.883)
PMID 18463891 · one of two readings recorded this
time to exhaustion cycling at 95% VO2peak after 5 min at 70% VO2peak, 4 h after rehydration with drinks of 1, 31, 40 or 50 mmol/l sodium chloride; urine output
no effect, time to exhaustion not different between treatments, p = 0.883
Not recorded as a finding: the comparison was against another active treatment
Time to exhaustion in the exercise capacity test was not different between treatments (P = 0.883).
PMID 18463891 · one of two readings recorded this
urine output, 1 mmol/l drink versus 40 and 50 mmol/l drinks
decreases, p = 0.01, n = 8
more was produced with the 1 than the 40 and 50 mmol/l drinks (P < 0.01)
PMID 18463891 · one of two readings recorded this
blood pressure difference per difference in salt intake (INTERSALT)
increases
The population study identified a minimal impact of sodium intake on blood pressure (0.9 mm Hg/10 mmol difference in salt intake)
PMID 19121772 · one of two readings recorded this
cardiovascular events (TONE)
decreases
Cardiovascular events were highest in the usual care group (83%) and lowest in the sodium reduction-plus-weight loss group (56%)
PMID 19121772 · one of two readings recorded this
cardiovascular events (TONE)
Cardiovascular events were highest in the usual care group (83%) and lowest in the sodium reduction-plus-weight loss group (56%)
PMID 19121772 · one of two readings recorded this
median systolic blood pressure (meta-analysis of 11 long-term trials)
decreases
A systematic review of 11 long-term controlled randomized trials reported a small decrease (1.1 mm Hg) in median systolic but not diastolic blood pressure with a reduced dietary sodium intake
PMID 19121772 · one of two readings recorded this
Muscle cramping frequency
no effect, n = 13
None of the volunteers experienced cramping
PMID 19295955 · one of two readings recorded this
Plasma osmolality
decreases, p = 0.05, n = 13
The same trends were observed for plasma osmolality (P < .05)
PMID 19295955 · one of two readings recorded this
Plasma volume change
decreases, n = 13
Albeit not significant, plasma volume was preserved during the HNa and LNa trials, but a reduction of 2.5% was observed in the W and PL trials
PMID 19295955 · one of two readings recorded this
Plasma volume change
decreases, n = 13
Albeit not significant, plasma volume was preserved during the HNa and LNa trials, but a reduction of 2.5% was observed in the W and PL trials
PMID 19295955 · one of two readings recorded this
Serum sodium concentration at end of protocol
no effect, n = 13
serum sodium concentration at the end of the protocol was 137.3 mmol/L and 136.7 mmol/L, respectively
PMID 19295955 · one of two readings recorded this
Serum sodium concentration at end of protocol
no effect, n = 13
serum sodium concentration at the end of the protocol was 137.3 mmol/L and 136.7 mmol/L, respectively
PMID 19295955 · one of two readings recorded this
Serum sodium concentration at end of protocol
decreases, p = 0.05, n = 13
a clear decrease was observed in W (134.5 +/- 0.8 mmol/L) and PL (134.4 +/- 0.8 mmol/L) trials compared with HNa and LNa trials (P < .05)
PMID 19295955 · one of two readings recorded this
Serum sodium concentration at end of protocol
decreases, p = 0.05, n = 13
a clear decrease was observed in W (134.5 +/- 0.8 mmol/L) and PL (134.4 +/- 0.8 mmol/L) trials compared with HNa and LNa trials (P < .05)
PMID 19295955 · one of two readings recorded this
serum sodium concentration at the end of 3 h exercise in the heat plus calf-raise and steep walking, carbohydrate-electrolyte drinks at 36.2 and 19.9 mmol/L sodium versus mineral water and coloured flavoured distilled water
increases, n = 13
Not recorded as a finding: the intervention held more than the compound
However, a clear decrease was observed in W (134.5 +/- 0.8 mmol/L) and PL (134.4 +/- 0.8 mmol/L) trials compared with HNa and LNa trials (P < .05).
PMID 19295955 · one of two readings recorded this
serum sodium concentration at the end of 3 h exercise in the heat with calf-raise and steep-walk protocol; plasma osmolality, plasma volume, cramping frequency
no effect
Not recorded as a finding: the intervention held more than the compound
During both HNa and LNa trials, serum sodium remained relatively constant (serum sodium concentration at the end of the protocol was 137.3 mmol/L and 136.7 mmol/L, respectively).
PMID 19295955 · one of two readings recorded this
pulse wave analysis, systolic and diastolic blood pressure
no effect
There was also no change in pulse wave analysis, systolic or diastolic blood pressure between interventions
PMID 22171802 · one of two readings recorded this
pulse wave velocity (PWV); also pulse wave analysis, systolic and diastolic blood pressure, after 4 weeks of sodium-free (A), 90 mmol Na (B) or 140 mmol Na (C) tomato juice on a 60 mmol/day low-sodium diet
no effect, PWV B-A 0.00 m/s (95% CI -0.30, 0.31); C-A 0.01 m/s (95% CI -0.38, 0.40)
Not recorded as a finding: the supporting sentence never names the compound
There was no difference in PWV between interventions (B-A 0.00 m/s, 95% CI: -0.30, 0.31 m/s; C-A 0.01 m/s, 95% CI: -0.38, 0.40 m/s).
PMID 22171802 · one of two readings recorded this
pulse wave velocity (PWV), segment and device not stated, after sodium-free versus 90 and 140 mmol Na tomato juice for 4 weeks
no effect, B-A 0.00 m/s (95% CI -0.30, 0.31); C-A 0.01 m/s (95% CI -0.38, 0.40)
Not recorded as a finding: the supporting sentence never names the compound
There was no difference in PWV between interventions (B-A 0.00 m/s, 95% CI: -0.30, 0.31 m/s; C-A 0.01 m/s, 95% CI: -0.38, 0.40 m/s).
PMID 22171802 · one of two readings recorded this
pulse wave velocity
no effect, n = 23
There was no difference in PWV between interventions (B-A 0.00 m/s, 95% CI: -0.30, 0.31 m/s; C-A 0.01 m/s, 95% CI: -0.38, 0.40 m/s)
PMID 22171802 · one of two readings recorded this
pulse wave velocity
no effect, n = 23
There was no difference in PWV between interventions (B-A 0.00 m/s, 95% CI: -0.30, 0.31 m/s; C-A 0.01 m/s, 95% CI: -0.38, 0.40 m/s)
PMID 22171802 · one of two readings recorded this
urinary sodium excretion
increases
There was an appropriate increase in urinary sodium excretion in the added sodium interventions
PMID 22171802 · one of two readings recorded this
24 h mean blood pressure (salt resistance check)
no effect, p = 0.05, n = 12
LS: 84 ± 1 mmHg vs. HS: 85 ± 2 mmHg; P > 0.05
PMID 22907057 · one of two readings recorded this
cutaneous microvascular function, plateau percent of maximal cutaneous vascular conductance during local heating by laser Doppler flowmetry, 7-day high-sodium (350 mmol/day) versus 7-day low-sodium (20 mmol/day) controlled diet
decreases, plateau %CVCmax LS 93 +/- 1 vs HS 80 +/- 2, n = 12
Not recorded as a finding: the comparison was against another active treatment
The plateau % CVCmax was reduced during HS (LS: 93 ± 1 % CVCmax vs. HS: 80 ± 2 % CVCmax; P < 0.05).
PMID 22907057 · one of two readings recorded this
cutaneous microvascular function, plateau percent of maximal cutaneous vascular conductance during local heating to 42 C, laser Doppler flowmetry with microdialysis
decreases, plateau % CVCmax 93 +/- 1 on low sodium versus 80 +/- 2 on high sodium
Not recorded as a finding: this platform holds no node for the endpoint
The plateau % CVCmax was reduced during HS (LS: 93 ± 1 % CVCmax vs. HS: 80 ± 2 % CVCmax; P < 0.05).
PMID 22907057 · one of two readings recorded this
Nitric oxide contribution to vasodilatation (L-NAME), ascorbic acid vs Ringer
increases, p = 0.05, n = 12
restored the NO contribution (Ringer: 44 ± 3 % CVCmax vs. AA: 59 ± 6 % CVCmax; P < 0.05)
PMID 22907057 · one of two readings recorded this
Plateau cutaneous vascular conductance during local heating, ascorbic acid vs Ringer
increases, p = 0.05, n = 12
During the HS diet, AA improved the plateau % CVCmax (Ringer: 80 ± 2 % CVCmax vs. AA: 89 ± 3 % CVCmax; P < 0.05)
PMID 22907057 · one of two readings recorded this
Plateau cutaneous vascular conductance during local heating (Ringer site)
decreases, p = 0.05, n = 12
The plateau % CVCmax was reduced during HS (LS: 93 ± 1 % CVCmax vs. HS: 80 ± 2 % CVCmax; P < 0.05)
PMID 22907057 · one of two readings recorded this
Sodium excretion
increases, p = 0.05, n = 12
Sodium excretion increased during the HS diet (P < 0.05)
PMID 22907057 · one of two readings recorded this
HDL cholesterol
no effect
High density lipoprotein cholesterol cholesterol (mmol/L) | 9 | 2031 | 0 | −0.01 (−0.03 to 0.00)
PMID 23558163 · one of two readings recorded this
LDL cholesterol
no effect
Low density lipoprotein cholesterol (mmol/L) | 6 | 1909 | 0 | 0.03 (−0.02 to 0.08)
PMID 23558163 · one of two readings recorded this
triglyceride
no effect
Triglyceride (mmol/L) | 8 | 2049 | 0 | 0.04 (−0.04 to 0.09)
PMID 23558163 · one of two readings recorded this
all cause mortality, cohort studies, higher sodium intake
unclear
Not recorded as a finding: paper calls the result inconclusive, which is not a two-sided statement of no effect; follow-up horizon not stated in the sentence
The meta-analysis of seven studies with 10 comparisons reporting all cause mortality was inconclusive (risk ratio 1.06, 0.94 to 1.20) (table 3).
PMID 23558163 · one of two readings recorded this
all cause mortality, cohort studies, highest versus lowest sodium intake
RR 1.06 (0.94 to 1.20)
Not recorded as a finding: paper states the result is 'inconclusive' (RR 1.06, 0.94 to 1.20), which is neither a direction nor an absence of effect
The meta-analysis of seven studies with 10 comparisons reporting all cause mortality was inconclusive (risk ratio 1.06, 0.94 to 1.20) (table 3).
PMID 23558163 · one of two readings recorded this
all cause mortality
no effect
All cause mortality21 22 96 97 100 101 106 | 7 | 21 515 | 61 | 1.06 (0.94 to 1.20)
PMID 23558163 · one of two readings recorded this
cardiovascular disease, all events
no effect
All events‡21 22 94 96 100 101 106 107 | 9 | 46 483 | 78 | 1.12 (0.93 to 1.34)
PMID 23558163 · one of two readings recorded this
cardiovascular disease, combined fatal and non-fatal events
no effect
Combined fatal and non-fatal events§21 22 94 97 | 4 | 8698 | 77 | 1.08 (0.78 to 1.47)
PMID 23558163 · one of two readings recorded this
cardiovascular disease, fatal events
no effect
Fatal events21 22 96 100 101 106 107 | 7 | 41 881 | 80 | 1.08 (0.87 to 1.33)
PMID 23558163 · one of two readings recorded this
cardiovascular events (randomised controlled trials)
no effect
(risk ratio 0.84, 95% confidence interval 0.57 to 1.23)
PMID 23558163 · one of two readings recorded this
coronary heart disease, all events
no effect
All events22 94 100 101 106 107 | 6 | 37 343 | 68 | 1.04 (0.86 to 1.24)
PMID 23558163 · one of two readings recorded this
coronary heart disease, combined fatal and non-fatal events
no effect
Combined fatal and non-fatal events22 94 100 101 106 | 5 | 13 851 | 72 | 1.02 (0.83 to 1.24)
PMID 23558163 · one of two readings recorded this
coronary heart disease, fatal events
increases
Fatal events101 106 107 | 3 | 30 670 | 0 | 1.32 (1.13 to 1.53)
PMID 23558163 · one of two readings recorded this
creatinine clearance
no effect
Creatinine clearance (mL/min) | 2 | 232 | 0 | −7.67 (−16.17 to 0.83)
PMID 23558163 · one of two readings recorded this
fatal coronary heart disease events, cohort studies, higher sodium intake
increases
Not recorded as a finding: fatal-only coronary events do not match the coronary-heart-disease-incidence node (fatal and non-fatal events)
The meta-analysis of three studies with five comparisons of sodium intake and coronary heart disease mortality detected an increased risk of fatal coronary heart disease events with higher sodium intake (1.32, 1.13 to 1.53).
PMID 23558163 · one of two readings recorded this
fatal coronary heart disease events, cohort studies
increases, 1.32 (1.13 to 1.53)
Not recorded as a finding: no node for coronary heart disease mortality (coronary-heart-disease-incidence is fatal and non-fatal events)
The meta-analysis of three studies with five comparisons of sodium intake and coronary heart disease mortality detected an increased risk of fatal coronary heart disease events with higher sodium intake (1.32, 1.13 to 1.53).
PMID 23558163 · one of two readings recorded this
glomerular filtration rate
no effect
Glomerular filtration rate (mL/min/1.73 m2) | 1 | 78 | NA | −5.00 (−15.25 to 5.25)
PMID 23558163 · one of two readings recorded this
plasma adrenaline
no effect
Plasma adrenaline (pg/mL) | 4 | 168 | 0 | 6.90 (−2.17 to 15.96)
PMID 23558163 · one of two readings recorded this
plasma noradrenaline
no effect
Plasma noradrenaline (pg/mL) | 7 | 265 | 32 | 8.23 (−27.84 to 44.29)
PMID 23558163 · one of two readings recorded this
protein:creatinine ratio
decreases
Protein:creatinine ratio (mg protein:mmol creatinine) | 1 | 198 | NA | −0.40 (−0.73 to −0.07)
PMID 23558163 · one of two readings recorded this
resting diastolic blood pressure
decreases
resting diastolic blood pressure by 1.54 mm Hg (0.98 to 2.11)
PMID 23558163 · one of two readings recorded this
resting diastolic blood pressure
decreases
reducing sodium intake decreased resting diastolic blood pressure by 0.87 mm Hg (0.14 to 1.60 mm Hg)
PMID 23558163 · one of two readings recorded this
resting diastolic blood pressure
decreases
systolic blood pressure by 3.14 mm Hg (0.30 to 5.98 mm Hg) and diastolic blood pressure by 1.70 mm Hg (0.33 to 3.07 mm Hg)
PMID 23558163 · one of two readings recorded this
resting diastolic blood pressure
no effect
a non-significant decrease in systolic blood pressure of 8.00 mm Hg (−1.73 to 17.73 mm Hg) and diastolic blood pressure of 4.00 mm Hg (−1.58 to 9.58 mm Hg)
PMID 23558163 · one of two readings recorded this
resting diastolic blood pressure
decreases
systolic blood pressure by 3.47 mm Hg (0.76 to 6.18 mm Hg) and diastolic blood pressure by 1.81 mm Hg (0.54 to 3.08 mm Hg) when sodium intake was <2 g/day compared with ≥2 g/day
PMID 23558163 · one of two readings recorded this
resting diastolic blood pressure
no effect
<1.2 | 3 | 209 | 0 | −6.39 (−9.53 to −3.25) | 65 | −2.47 (−5.86 to 0.92)
PMID 23558163 · one of two readings recorded this
resting diastolic blood pressure
decreases
<2 | 16 | 2415 | 68 | −3.39 (−4.69 to −2.09) | 71 | −1.54 (−2.46 to −0.63)
PMID 23558163 · one of two readings recorded this
resting diastolic blood pressure
decreases
Automatic | 17 | 1678 | 3 | −4.04 (−5.10 to −2.97) | 33 | −1.75 (−2.54 to −0.95)
PMID 23558163 · one of two readings recorded this
resting diastolic blood pressure
no effect
Combination home** | 1 | 16 | NA | −9.00 (−18.32 to 0.32) | NA | −1.00 (−5.44 to 3.44)
PMID 23558163 · one of two readings recorded this
resting diastolic blood pressure
no effect
Combination office¶ | 1 | 16 | NA | −7.00 (−14.84 to 0.84) | NA | −1.00 (−6.00 to 4.00)
PMID 23558163 · one of two readings recorded this
resting diastolic blood pressure
decreases
Crossover | 22 | 2849 | 63 | −4.04 (−5.27 to −2.81) | 54 | −1.70 (−2.43 to −0.97)
PMID 23558163 · one of two readings recorded this
resting diastolic blood pressure
no effect
Mixed or not specified | 6 | 419 | 27 | −1.67 (−3.01 to −0.34) | 58 | −0.45 (−1.93 to 1.03)
PMID 23558163 · one of two readings recorded this
resting diastolic blood pressure
decreases
Hypertension | 24 | 2273 | 13 | −4.06 (−5.15 to −2.96) | 29 | −2.26 (−3.02 to −1.50)
PMID 23558163 · one of two readings recorded this
resting diastolic blood pressure
decreases
Male§ | 2 | 53 | 0 | −9.10 (−16.63 to −1.57) | 0 | −4.83 (−8.98 to −0.68)
PMID 23558163 · one of two readings recorded this
resting diastolic blood pressure
decreases
Manual | 19 | 5048 | 76 | −2.93 (−4.15 to −1.71) | 70 | −1.40 (−2.18 to −0.62)
PMID 23558163 · one of two readings recorded this
resting diastolic blood pressure
decreases
Mixed | 34 | 6749 | 65 | −3.34 (−4.25 to −2.42) | 60 | −1.50 (−2.07 to −0.94)
PMID 23558163 · one of two readings recorded this
resting diastolic blood pressure
no effect
No hypertension | 7 | 3067 | 61 | −1.38 (−2.74 to −0.02) | 38 | −0.58 (−1.29 to 0.14)
PMID 23558163 · one of two readings recorded this
resting diastolic blood pressure
decreases
Not taking drugs | 27 | 5456 | 71 | −3.66 (−4.85 to −2.47) | 62 | −1.70 (−2.37 to −1.04)
PMID 23558163 · one of two readings recorded this
resting diastolic blood pressure
decreases
Parallel | 16 | 4147 | 44 | −2.47 (−3.51 to −1.43) | 52 | −1.33 (−2.04 to −0.62)
PMID 23558163 · one of two readings recorded this
resting diastolic blood pressure
decreases
<1/3 of control | 8 | 3995 (4001) | 46 | −1.45 (−2.29 to −0.60) | 38 | −0.74 (−1.28 to −0.19)
PMID 23558163 · one of two readings recorded this
resting diastolic blood pressure
decreases
Seated office | 18 | 5542 | 76 | −2.91 (−3.99 to −1.82) | 74 | −1.38 (−2.07 to −0.68)
PMID 23558163 · one of two readings recorded this
resting diastolic blood pressure
decreases
Standing office | 8 | 705 | 0 | −4.44 (−6.92 to −1.96) | 0 | −1.86 (−3.34 to −0.38)
PMID 23558163 · one of two readings recorded this
resting diastolic blood pressure
decreases
Supine office | 15 | 1127 | 0 | −4.69 (−6.33 to −3.06) | 0 | −2.03 (−3.03 to −1.03)
PMID 23558163 · one of two readings recorded this
resting diastolic blood pressure
decreases
Taking drugs | 6 | 927 | 9 | −4.55 (−6.59 to −2.51) | 6 | −2.05 (−3.19 to −0.91)
PMID 23558163 · one of two readings recorded this
resting diastolic blood pressure
decreases
3-6 | 5 | 2817 | 67 | −1.91 (−3.60 to −0.23) | 67 | −1.33 (−2.50 to −0.15)
PMID 23558163 · one of two readings recorded this
resting diastolic blood pressure
decreases
<3 | 31 | 3351 | 51 | −4.07 (−5.12 to −3.02) | 49 | −1.67 (−2.33 to −1.02)
PMID 23558163 · one of two readings recorded this
resting diastolic blood pressure
no effect
>6 | 3 | 2862 | 59 | −0.88 (−2.00 to 0.23) | 56 | −0.45 (−1.25 to 0.34)
PMID 23558163 · one of two readings recorded this
resting systolic and diastolic blood pressure, randomised trials of reduced versus higher sodium intake
decreases, systolic -3.39 mm Hg (95% CI 2.46 to 4.31); diastolic -1.54 mm Hg (0.98 to 2.11)
Not recorded as a finding: comparator is a higher sodium intake (dose against dose), and blood pressure acquisition setting is mixed across trials
The meta-analysis of 36 studies contributing 49 comparisons found that a reduction in sodium intake significantly reduced resting systolic blood pressure by 3.39 mm Hg (95% confidence interval 2.46 to 4.31 mm Hg) (fig 2) and resting diastolic blood pressure by 1.54 mm Hg (0.98 to 2.11).
PMID 23558163 · one of two readings recorded this
resting systolic blood pressure
decreases
a reduction in sodium intake significantly reduced resting systolic blood pressure by 3.39 mm Hg (95% confidence interval 2.46 to 4.31 mm Hg)
PMID 23558163 · one of two readings recorded this
resting systolic blood pressure
decreases
reducing sodium intake decreased resting systolic blood pressure by 0.84 mm Hg (0.25 to 1.43 mm Hg)
PMID 23558163 · one of two readings recorded this
resting systolic blood pressure
decreases
a significant reduction in systolic blood pressure of 0.71mm Hg (0.07 to 1.35 mm Hg) was detected
PMID 23558163 · one of two readings recorded this
resting systolic blood pressure
no effect
the reduction in blood pressure was no longer significant (0.62 mm Hg, −0.25 to 1.5 mm Hg)
PMID 23558163 · one of two readings recorded this
resting systolic blood pressure
decreases
systolic blood pressure by 3.14 mm Hg (0.30 to 5.98 mm Hg) and diastolic blood pressure by 1.70 mm Hg (0.33 to 3.07 mm Hg)
PMID 23558163 · one of two readings recorded this
resting systolic blood pressure
no effect
a non-significant decrease in systolic blood pressure of 8.00 mm Hg (−1.73 to 17.73 mm Hg) and diastolic blood pressure of 4.00 mm Hg (−1.58 to 9.58 mm Hg)
PMID 23558163 · one of two readings recorded this
resting systolic blood pressure
decreases
systolic blood pressure by 3.47 mm Hg (0.76 to 6.18 mm Hg) and diastolic blood pressure by 1.81 mm Hg (0.54 to 3.08 mm Hg) when sodium intake was <2 g/day compared with ≥2 g/day
PMID 23558163 · one of two readings recorded this
resting systolic blood pressure
decreases
<1.2 | 3 | 209 | 0 | −6.39 (−9.53 to −3.25) | 65 | −2.47 (−5.86 to 0.92)
PMID 23558163 · one of two readings recorded this
resting systolic blood pressure
decreases
<2 | 16 | 2415 | 68 | −3.39 (−4.69 to −2.09) | 71 | −1.54 (−2.46 to −0.63)
PMID 23558163 · one of two readings recorded this
resting systolic blood pressure
decreases
Automatic | 17 | 1678 | 3 | −4.04 (−5.10 to −2.97) | 33 | −1.75 (−2.54 to −0.95)
PMID 23558163 · one of two readings recorded this
resting systolic blood pressure
no effect
Combination home** | 1 | 16 | NA | −9.00 (−18.32 to 0.32) | NA | −1.00 (−5.44 to 3.44)
PMID 23558163 · one of two readings recorded this
resting systolic blood pressure
no effect
Combination office¶ | 1 | 16 | NA | −7.00 (−14.84 to 0.84) | NA | −1.00 (−6.00 to 4.00)
PMID 23558163 · one of two readings recorded this
resting systolic blood pressure
decreases
Crossover | 22 | 2849 | 63 | −4.04 (−5.27 to −2.81) | 54 | −1.70 (−2.43 to −0.97)
PMID 23558163 · one of two readings recorded this
resting systolic blood pressure
decreases
Mixed or not specified | 6 | 419 | 27 | −1.67 (−3.01 to −0.34) | 58 | −0.45 (−1.93 to 1.03)
PMID 23558163 · one of two readings recorded this
resting systolic blood pressure
decreases
Hypertension | 24 | 2273 | 13 | −4.06 (−5.15 to −2.96) | 29 | −2.26 (−3.02 to −1.50)
PMID 23558163 · one of two readings recorded this
resting systolic blood pressure
decreases
Male§ | 2 | 53 | 0 | −9.10 (−16.63 to −1.57) | 0 | −4.83 (−8.98 to −0.68)
PMID 23558163 · one of two readings recorded this
resting systolic blood pressure
decreases
Manual | 19 | 5048 | 76 | −2.93 (−4.15 to −1.71) | 70 | −1.40 (−2.18 to −0.62)
PMID 23558163 · one of two readings recorded this
resting systolic blood pressure
decreases
Mixed | 34 | 6749 | 65 | −3.34 (−4.25 to −2.42) | 60 | −1.50 (−2.07 to −0.94)
PMID 23558163 · one of two readings recorded this
resting systolic blood pressure
decreases
No hypertension | 7 | 3067 | 61 | −1.38 (−2.74 to −0.02) | 38 | −0.58 (−1.29 to 0.14)
PMID 23558163 · one of two readings recorded this
resting systolic blood pressure
decreases
Not taking drugs | 27 | 5456 | 71 | −3.66 (−4.85 to −2.47) | 62 | −1.70 (−2.37 to −1.04)
PMID 23558163 · one of two readings recorded this
resting systolic blood pressure
decreases
Parallel | 16 | 4147 | 44 | −2.47 (−3.51 to −1.43) | 52 | −1.33 (−2.04 to −0.62)
PMID 23558163 · one of two readings recorded this
resting systolic blood pressure
decreases
<1/3 of control | 8 | 3995 (4001) | 46 | −1.45 (−2.29 to −0.60) | 38 | −0.74 (−1.28 to −0.19)
PMID 23558163 · one of two readings recorded this
resting systolic blood pressure
decreases
Seated office | 18 | 5542 | 76 | −2.91 (−3.99 to −1.82) | 74 | −1.38 (−2.07 to −0.68)
PMID 23558163 · one of two readings recorded this
resting systolic blood pressure
decreases
Standing office | 8 | 705 | 0 | −4.44 (−6.92 to −1.96) | 0 | −1.86 (−3.34 to −0.38)
PMID 23558163 · one of two readings recorded this
resting systolic blood pressure
decreases
Supine office | 15 | 1127 | 0 | −4.69 (−6.33 to −3.06) | 0 | −2.03 (−3.03 to −1.03)
PMID 23558163 · one of two readings recorded this
resting systolic blood pressure
decreases
Taking drugs | 6 | 927 | 9 | −4.55 (−6.59 to −2.51) | 6 | −2.05 (−3.19 to −0.91)
PMID 23558163 · one of two readings recorded this
resting systolic blood pressure
decreases
3-6 | 5 | 2817 | 67 | −1.91 (−3.60 to −0.23) | 67 | −1.33 (−2.50 to −0.15)
PMID 23558163 · one of two readings recorded this
resting systolic blood pressure
decreases
<3 | 31 | 3351 | 51 | −4.07 (−5.12 to −3.02) | 49 | −1.67 (−2.33 to −1.02)
PMID 23558163 · one of two readings recorded this
resting systolic blood pressure
no effect
>6 | 3 | 2862 | 59 | −0.88 (−2.00 to 0.23) | 56 | −0.45 (−1.25 to 0.34)
PMID 23558163 · one of two readings recorded this
serum creatinine
no effect
Serum creatinine (µmol/L) | 5 | 728 | 0 | 1.68 (−0.65 to 4.00)
PMID 23558163 · one of two readings recorded this
stroke, all events
increases
All events21 22 100-104 106 107 | 10 | 72 878 | 49 | 1.24 (1.08 to 1.43)
PMID 23558163 · one of two readings recorded this
stroke, combined fatal and non-fatal events
increases
Combined fatal and non-fatal events21 22 100-103 106 | 8 | 28 974 | 20 | 1.13 (1.01 to 1.26)
PMID 23558163 · one of two readings recorded this
stroke, fatal events
increases
Fatal events101 104 107 | 3 | 48 645 | 33 | 1.63 (1.27 to 2.10)
PMID 23558163 · one of two readings recorded this
total cholesterol
no effect
Total cholesterol (mmol/L) | 11 | 2339 | 0 | 0.02 (−0.03 to 0.07)
PMID 23558163 · one of two readings recorded this
urinary adrenaline (epinephrine)
no effect
Urinary adrenaline (epinephrine, pg/mL) | 1 | 18 | NA | −13.10 (−29.24 to 3.04)
PMID 23558163 · one of two readings recorded this
urinary noradrenaline (norepinephrine)
no effect
Urinary noradrenaline (norepinephrine, pg/mL) | 2 | 53 | 0 | 17.13 (−34.06 to 68.33)
PMID 23558163 · one of two readings recorded this
urinary protein excretion
no effect
Urinary protein excretion (µmol/L) | 1 | 198 | NA | −76.61 (−154.20 to 0.97)
PMID 23558163 · one of two readings recorded this
resting blood pressure
no effect, n = 70
Diet did not affect resting blood pressure
PMID 24284498 · one of two readings recorded this
resting heart rate
decreases, p = 0.02, n = 70
heart rate (HR) (mean ± SE) was 66 ± 1, 64 ± 1, and 63 ± 1 bpm in low, normal, and high sodium conditions, respectively (analysis of variance P = 0.02)
PMID 24284498 · one of two readings recorded this
resting HRV: LFnu increase and SDNN, RMSSD, HFnu decrease, low vs normal and high sodium
modulates, p = 0.05, n = 70
with increased LFnu and decreased SDNN, RMSSD, and HFnu compared to both normal and high sodium conditions (P ≤0.05 for all)
PMID 24284498 · one of two readings recorded this
resting HRV: SDNN, RMSSD, high frequency, LFnu and HFnu, main effect of sodium
modulates, p = 0.01, n = 70
high frequency, low-frequency normalized units (LFnu), and high-frequency normalized units (HFnu) (P < 0.01 for all)
PMID 24284498 · one of two readings recorded this
sodium-by-mental stress interaction on mean NN, RMSSD, high-frequency power, LFnu and LF/HF ratio
modulates, p = 0.05, n = 70
Dietary sodium-by-mental stress interactions were significant for mean NN, RMSSD, high-frequency power, LFnu, and low frequency/high frequency ratio (P < 0.05 for all)
PMID 24284498 · one of two readings recorded this